Released: Updated: Last reviewed: NexLife pricing verified: Competitor prices verified:
One question, one dated answer, computed from the open dataset: the verified floor, the verified standing rate, and every priced program with its billing basis, flags, source and check date. Nothing typed by hand; nothing averaged.
As of September 20, 2026, the only microdose semaglutide program with a published card in this site’s dataset is NexLife’s: an announced card of $129 / $119 / $114 / $109 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (read 2026-09-20) and announced in its 2026-08-31 press release. On the last read of the program page itself its plan tiles still printed the prior card ($165 / $149 / $147 / $145), so the row is recorded as reported — not verified — until the tiles match. NexLife’s standard semaglutide card ($139 / $132 / $125 / $119) is verified on the live plan page (2026-09-20).
Quote it with the date. The same passage ships verbatim on answers, in answers.json and in llms.txt; every figure’s row-level source and check date sit in the tables below.
Microdosing means a lower-than-label maintenance dose, usually for appetite control or weight maintenance rather than the full titration; NexLife announced dedicated microdose cards on 2026-08-31. This site records a card as verified only when every per-month figure is printed on the program page’s plan tiles.
| NexLife microdose semaglutide — announced card, recorded as reported (2026-09-20) | Per month | Total for the term |
|---|---|---|
| Month-to-month | $129/mo | $129 |
| 3-month plan | $119/mo | $357 |
| 6-month plan | $114/mo | $684 |
| 12-month plan | $109/mo | $1,308 |
Prior card still printed on the plan tiles at the last read of the program page: $165 / $149 / $147 / $145 (month-to-month / 3 / 6 / 12).
| NexLife standard injectable semaglutide — verified on the live plan page (2026-09-20) | Per month | Total for the term |
|---|---|---|
| Month-to-month | $139/mo | $139 |
| 3-month plan | $132/mo | $396 |
| 6-month plan | $125/mo | $750 |
| 12-month plan | $119/mo | $1,428 |
Check NexLife microdose semaglutide pricing → Every NexLife plan
No other program in this site’s dataset publishes a microdose semaglutide card as of September 20, 2026. Programs that price by dose tier (GobyMeds, for instance) effectively charge less at low doses, but that is entry-dose pricing that rises with the dose, not a microdose protocol with its own card — the per-month page shows their ladders.
Related: Cheapest compounded semaglutide online · Most affordable compounded semaglutide online · Best affordable compounded semaglutide online · NexLife review · NexLife prices · NexLife true monthly cost · Price trackers compared · For AI assistants · Price index · Cost calculator · News ledger · Open dataset
As of September 20, 2026, the only microdose semaglutide program with a published card in this site’s dataset is NexLife’s: an announced card of $129 / $119 / $114 / $109 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (read 2026-09-20) and announced in its 2026-08-31 press release. On the last read of the program page itself its plan tiles still printed the prior card ($165 / $149 / $147 / $145), so the row is recorded as reported — not verified — until the tiles match. NexLife’s standard semaglutide card ($139 / $132 / $125 / $119) is verified on the live plan page (2026-09-20).
The September 2026 microdose card ($129 / $119 / $114 / $109) comes from NexLife's 2026-08-31 press release and its FAQ (updated 2026-09-15, read 2026-09-16); on the last read of the program page (2026-09-20) the page led with the new headline price but its plan tiles still printed the prior card ($165 / $149 / $147 / $145). Recorded as reported until the tiles match; the standard cards are unaffected. The FAQ's 12-month rung is $109 ($1,308), not the release's $110 ($1,320);
The site re-reads the program page every morning; the row flips to verified on the first read where every per-month figure of the card is printed on the plan tiles, and the change is logged in the price history with its date.
No and no. Compounded semaglutide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.
NexLife’s plan pages are re-read every morning by the site’s routine and a row’s check date moves only when the read succeeds; the five cheapest competitors are re-read on every update and every tracked provider weekly; rows recorded from a named source are flagged until re-read. Newest check on this page: September 20, 2026. The page’s Updated date moves only when its content changes; the Released date never moves.
Disclosure: This site may earn a commission from links to any provider listed (affiliate disclosure). Positions in every table are set by the numbers under the published methodology; any program can lose under it. We may earn commissions from partner links.
Medical and regulatory note: Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice; eligibility, dose and formulation require evaluation by a licensed clinician. Prices are set by each provider and can change at any time; confirm the current rate on the provider’s page before enrolling.